skip to Main Content

Marapharm Ventures Inc. announces an expansion of its cannabis delivery service

We are immediately expanding the cannabis delivery services business. We’ve created a unique model, software and an operating system for deliveries that would operate similarly to a private driver service. The immediate expansion will be into the states of Nevada and Arizona. The plan is to go into all states that have legal medical or recreational use of cannabis. Internal proformas indicate that several hundred thousand dollars of revenue can be produced monthly from each state and we are anxious to see if we are right! “Linda Sampson, Marapharm, CEO.

Kelowna British Columbia. On February 20, 2017 Marapharm announced it had entered into an agreement to purchase a Medical Delivery Service with the specific and limited purpose to deliver, facilitate or coordinate cannabis transactions between qualified patients and caregivers. The delivery service is located in California.

Marapharm purchased 80% of the shares of Moringa Cooperative, Inc. “Moringa”  The purpose of the corporation is to engage in any lawful activity and specific to cannabis transactions in California.


Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for it’s land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (, the OTC website ( and Sedar website ( under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION:    contact 778-583-4476    email

Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

Back To Top